RxDoctor Payments Data

Reema Aljamal, MD

Family Medicine · West Orange, NJNPI 1316434830

Payments from drug & device makers

$2,411in general payments, 2019–2025

Across 121 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$364
  • Pfizer$266
  • GSK$145
  • Abiomed$115
  • Exact Sciences$110
  • plus $393 from 9 others

What the payments were for

  • Travel & lodging$412%
  • Food & beverage$2,37198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk57$1,019
AstraZeneca14$364
Pfizer15$266
GSK9$145
Abiomed1$115
Exact Sciences4$110
Amgen6$94
Artivion, Inc.2$75
Lilly USA, LLC3$57
Genentech USA, Inc.4$56
Gilead2$35
Astellas Pharma US Inc1$23
Merck1$22
Phadia US Inc.1$18
VBI Vaccine (delaware) Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,411 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$84,488
Medicare patients
191
Services billed
2,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol25$25,670
RybelsusSemaglutide17$23,060
Azelastine-FluticasoneAzelastine/Fluticasone16$2,117
Valsartan59$1,405
Rosuvastatin Calcium107$1,356
Atorvastatin Calcium125$957
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide27$708
Amlodipine Besylate125$696
Fluticasone Propionate55$658
Albuterol Sulfate HfaAlbuterol Sulfate30$484
Azelastine Hcl19$405
Metformin Hcl82$373
Tamsulosin Hcl35$372
Omeprazole19$258
Metoprolol Succinate21$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$364$25,67025 claims
Novo NordiskRybelsus$1,019$23,06017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →